Cynosure Lutronic announced on the 18th that its dual monopolar radiofrequency (RF) medical device, XERF, has surpassed 2,000 units in global cumulative sales. This achievement comes just six months after reaching 1,000 units in November 2025, indicating a sales velocity that has tripled compared to the initial sales phase, which took approximately 18 months.

The accelerated adoption of XERF underscores its solid positioning within a fiercely competitive energy-based devices market. The concomitant rise in demand for the accompanying consumable, the XERF Effectors, is establishing a robust symbiotic revenue model, propelling both equipment and consumable sales.

XERF marks the first next-generation RF device introduced since Cynosure Lutronic's merger, featuring a dual monopolar method that combines a standard frequency of 6.78 MHz with an additional 2 MHz frequency. This advancement allows for depth-adjustable energy delivery in three levels, facilitating tailored treatments. The patented 'Spider Pattern' applied in the XERF Effectors supports larger treatment sizes up to 20x30mm, maximizing procedural efficiency while integrating technologies like Wave Fit Pulse and an ICD cooling system for pain-free operation.

The device's expanding approval footprint includes key international markets, with launches in 13 countries, starting with Korea in May 2024. Following its introduction to North America last year, XERF saw sales exceed 400 units in less than six months, demonstrating strong market reception. Recent regulatory approval from the Australian Therapeutic Goods Administration (TGA) has solidified its footing in the Oceania market.

Cynosure Lutronic adopts a two-track localization strategy, operating a direct sales model in seven key markets (U.S., Korea, Canada, Japan, China, Germany, and Spain) while partnering with competitive distributors in other regions. This approach has proven effective in enhancing local presence and addressing regional demands.

Furthermore, global academic networking has fostered sales acceleration. Earlier this year, at the IMCAS Paris 2026 held in France, Cynosure Lutronic shared the clinical value of its dual monopolar RF technology with international medical personnel, further establishing its academic expertise in the field.